Kristian Reich - MoonLake Immunotherapeuti CoFounder Officer
| MLTX Stock | USD 55.47 1.04 1.91% |
Insider
Kristian Reich is CoFounder Officer of MoonLake Immunotherapeutics
| Age | 58 |
| Address | Dorfstrasse 29, Zug, Switzerland, 6300 |
| Phone | 41 415108022 |
| Web | https://www.moonlaketx.com |
Latest Insider Transactions
Kristian Reich Latest Insider Activity
Tracking and analyzing the buying and selling activities of Kristian Reich against MoonLake Immunotherapeuti stock is an integral part of due diligence when investing in MoonLake Immunotherapeuti. Kristian Reich insider activity provides valuable insight into whether MoonLake Immunotherapeuti is net buyers or sellers over its current business cycle. Note, MoonLake Immunotherapeuti insiders must abide by specific rules, including filing SEC forms every time they buy or sell MoonLake Immunotherapeuti'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Kristian Reich over two months ago Disposition of 10000 shares by Kristian Reich of MoonLake Immunotherapeuti at 60.15 subject to Rule 16b-3 | ||
Kristian Reich over six months ago Disposition of 29431 shares by Kristian Reich of MoonLake Immunotherapeuti at 55.0 subject to Rule 16b-3 | ||
Kristian Reich over six months ago Disposition of 10000 shares by Kristian Reich of MoonLake Immunotherapeuti at 60.15 subject to Rule 16b-3 |
MoonLake Immunotherapeuti Management Efficiency
The company has return on total asset (ROA) of (0.1332) % which means that it has lost $0.1332 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.168) %, meaning that it created substantial loss on money invested by shareholders. MoonLake Immunotherapeuti's management efficiency ratios could be used to measure how well MoonLake Immunotherapeuti manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.07 in 2024. Return On Capital Employed is likely to rise to -0.1 in 2024. At this time, MoonLake Immunotherapeuti's Total Assets are fairly stable compared to the past year. Other Current Assets is likely to rise to about 2.2 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 11.8 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Bill DeGrado | Pliant Therapeutics | N/A | |
| Weidong Zhong | Terns Pharmaceuticals | 58 | |
| Kerry MD | Terns Pharmaceuticals | N/A | |
| Joshua Cohen | Amylyx Pharmaceuticals | 32 | |
| Melissa Abel | 89bio Inc | N/A | |
| Neeraj Teotia | Arcellx | 49 | |
| Mark Vignola | Terns Pharmaceuticals | 46 | |
| Charles II | Day One Biopharmaceuticals | 47 | |
| MBA MR | Aerovate Therapeutics | 62 | |
| CFA CFA | Travere Therapeutics | 40 | |
| Ryan Martins | 89bio Inc | 45 | |
| Rohan Palekar | 89bio Inc | 58 | |
| Jonathan JD | Compass Therapeutics | N/A | |
| Hal MD | Pliant Therapeutics | N/A | |
| Harry MD | 89bio Inc | 59 | |
| Prof MD | Ventyx Biosciences | N/A | |
| Donna Dea | Aerovate Therapeutics | N/A | |
| William JD | Akero Therapeutics | 51 | |
| Siew MS | Acumen Pharmaceuticals | N/A | |
| Susan Kalled | Compass Therapeutics | 61 | |
| Michelle Gilson | Arcellx | 31 | |
Management Performance
| Return On Equity | -0.17 | ||||
| Return On Asset | -0.13 |
MoonLake Immunotherapeuti Leadership Team
Elected by the shareholders, the MoonLake Immunotherapeuti's board of directors comprises two types of representatives: MoonLake Immunotherapeuti inside directors who are chosen from within the company, and outside directors, selected externally and held independent of MoonLake. The board's role is to monitor MoonLake Immunotherapeuti's management team and ensure that shareholders' interests are well served. MoonLake Immunotherapeuti's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, MoonLake Immunotherapeuti's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Tino Anthamatten, Market Marketing | ||
| Luciana Marques, People HR | ||
| Jorge Silva, CEO CoFounder | ||
| Nicolas Mosimann, General Counsel | ||
| Annett Zippel, Director Culture | ||
| Joana Cortez, Director Compliance | ||
| Oliver Daltrop, Chief Officer | ||
| Nuala Brennan, Chief Officer | ||
| Kristian Reich, CoFounder Officer | ||
| Matthias Bodenstedt, Chief Officer | ||
| Carla Bretes, Director Development |
MoonLake Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is MoonLake Immunotherapeuti a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.17 | ||||
| Return On Asset | -0.13 | ||||
| Current Valuation | 2.94 B | ||||
| Shares Outstanding | 63.06 M | ||||
| Shares Owned By Insiders | 15.22 % | ||||
| Shares Owned By Institutions | 98.14 % | ||||
| Number Of Shares Shorted | 8 M | ||||
| Price To Book | 7.03 X | ||||
| EBITDA | (54.11 M) | ||||
| Net Income | (44.08 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for MoonLake Stock Analysis
When running MoonLake Immunotherapeuti's price analysis, check to measure MoonLake Immunotherapeuti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MoonLake Immunotherapeuti is operating at the current time. Most of MoonLake Immunotherapeuti's value examination focuses on studying past and present price action to predict the probability of MoonLake Immunotherapeuti's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MoonLake Immunotherapeuti's price. Additionally, you may evaluate how the addition of MoonLake Immunotherapeuti to your portfolios can decrease your overall portfolio volatility.